Senti Biosciences (SNTI)

• Market cap: $35.3M
• 1 day: -2.17%
• 5 days: -2.88%
• 1 month: -8.78%
• 3 months: -52.8%
• 6 months: -59.58%
• Year to date: -64.57%
• 1 year: -56.45%
• 5 years: -98.65%
• 10 years: -98.65%
• Sector: Healthcare
• Industry: Biotechnology

About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Employees: 48

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

3.07% more ownership

Funds ownership: 22.77% [Q1] → 25.84% (+3.07%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

6% less funds holding

Funds holding: 16 [Q1] → 15 (-1) [Q2]

28% less capital invested

Capital invested by funds: $19.9M [Q1] → $14.2M (-$5.66M) [Q2]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Geulah Livshits

$12

Buy Maintained

8 Aug 2025